Canine parvovirus (CPV) virus-like particle (VLP) vaccines and uses thereof
AssigneeMerial Limited
InventorsFrederic David, Zahia Hannas-Djebbara, Herve Poulet, Jules Maarten Minke
Life of this patent
Estimating the term…
Abstract
The present invention encompasses canine parvovirus (CPV) vaccines or compositions. The vaccine or composition may be a vaccine or composition containing CPV virus-like particle (VLP), and a preparation method and a use thereof. The CPV VLPs provided by the invention are formed by the CPV VP2 protein. Further, the invention broadly encompasses vaccines comprising combinations of MLV and VLP, which are capable of overcoming MDA against a variety of pathogens, which infect a variety of different species.
Claims20
A combination vaccine comprising a canine parvovirus (CPV) virus-like particle (VLP) component and a CPV modified-live virus (MLV) component, wherein both the VLP and the MLV are directed against the same pathogen or disease, wherein the combination vaccine overcomes CPV-specific, maternally-derived antibodies (MDA), wherein the pathogen is CPV;
- and wherein the CPV MLV and CPV VLP are present in amounts such that the CPV VLPs synergize the induction of an immune response with the CPV MLV in MDA+ puppies when administered simultaneously.
A plasmid useful for producing CPV VLP, comprising a polynucleotide encoding a CPV antigen having a sequence as set forth in SEQ ID NO:
- 1, 3, 4, 6, or 8-10, or a polynucleotide sequence having at least 90% identity to a sequence as set forth in SEQ ID NO:
- 1, 3, 4, 6, or 8-10.
A substantially purified CPV empty capsid or CPV VLP expressed in insect cells, wherein the CPV empty capsid or VLP comprises a polypeptide having a sequence as set forth in SEQ ID NO:
- 1, 3, 4, 6, or 8-10;
- or,
- wherein the CPV empty capsid or VLP comprises a polypeptide having at least 90% identity to a sequence as set forth in SEQ ID NO:
- 1, 3, 4, 6, or 8-10.
Dependencies are inferred from the claim text.